Grand Pharmaceutical Group (FRA:MX6A) Long-Term Debt: €202 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MX6A Grand Pharmaceutical Group Ltd FRA:MX6A
88 GF Score
Price €0.54
GF Value €0.62
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grand Pharmaceutical Group Long-Term Debt?

Grand Pharmaceutical Group FRA:MX6A 88 Long-Term Debt is €202 Mil as of Dec. 2025. GuruFocus rates FRA:MX6A with a GF Score™ of 88/100 and a GF Value™ of €0.62 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Grand Pharmaceutical Group's Long-Term Debt for the quarter that ended in Dec. 2025 was €202 Mil.

Grand Pharmaceutical Group's quarterly Long-Term Debt increased from Dec. 2024 (€154 Mil) to Jun. 2025 (€198 Mil) and increased from Jun. 2025 (€198 Mil) to Dec. 2025 (€202 Mil).

Grand Pharmaceutical Group's annual Long-Term Debt increased from Dec. 2023 (€116 Mil) to Dec. 2024 (€154 Mil) and increased from Dec. 2024 (€154 Mil) to Dec. 2025 (€202 Mil).

Grand Pharmaceutical Group  (FRA:MX6A) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Grand Pharmaceutical Group Long-Term Debt Related Terms

Grand Pharmaceutical Group Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Grand Pharmaceutical Group's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Pharmaceutical Group Long-Term Debt Chart

Grand Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 171.36 140.93 116.25 154.34 202.04

Grand Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 116.25 240.79 154.34 197.82 202.04
FRA:MX6A
88GF Score
Grand Pharmaceutical Group Ltd FRA:MX6A
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €202 Mil mean?
Grand Pharmaceutical Group (FRA:MX6A) has a Long-Term Debt of €202 Mil as of Dec. 2025.
Is Grand Pharmaceutical Group's Long-Term Debt too high?
Grand Pharmaceutical Group's current Long-Term Debt is €202 Mil. Overall, Grand Pharmaceutical Group has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Long-Term Debt compare to ZTS?
Grand Pharmaceutical Group's Long-Term Debt of €202 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Grand Pharmaceutical Group's current Long-Term Debt is €202 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.62, compared to a current price of €0.54 — trading 12.9% below its estimated fair value. The current Long-Term Debt is €202 Mil. Grand Pharmaceutical Group's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current Long-Term Debt is €202 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?

Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.54 is trading 12.9% below its estimated GF Value™ of €0.62. GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for FRA:MX6A:

  • Long-Term Debt: €202 Mil
  • GF Value™: €0.62 vs. price of €0.54 (12.9% below fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong Kong
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
88GF Score

Get the complete analysis for FRA:MX6A

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.54
Price
€0.62
GF Value